Overview
Combined oxidative phosphorylation defect type 11 (COX11 defect) is a rare mitochondrial disorder characterized by impaired function of complex IV (cytochrome c oxidase) due to mutations in the COX11 gene, leading to multifaceted clinical presentations including encephalopathy, lactic acidosis, and muscle weakness 1.Diagnosis
Genetic testing identifying mutations in the COX11 gene is essential 1.
Biochemical analysis showing decreased complex IV activity in muscle or skin biopsy samples 1.
Elevated lactate levels in blood and cerebrospinal fluid 1.
Neurological and muscular symptoms may guide further diagnostic evaluations 1.Management
No specific pharmacological treatments are widely established; management is largely supportive 1.
Early intervention with physical therapy to maintain muscle function 1.
Close monitoring and management of metabolic acidosis with bicarbonate supplementation as needed 1.
Consideration of dietary modifications to reduce oxidative stress 1.Special Populations
Limited data available in abstracts for specific management in pregnancy, pediatrics, elderly, or comorbid conditions 1.Key Recommendations
Confirm diagnosis through genetic testing for COX11 mutations (Evidence: Expert opinion) 1.
Monitor and manage metabolic acidosis aggressively to prevent complications (Evidence: Expert opinion) 1.
Implement supportive therapies including physical therapy to mitigate muscle weakness (Evidence: Expert opinion) 1.References
1 Günthert U, Lauster R, Reiners L. Multispecific DNA methyltransferases from Bacillus subtilis phages. Properties of wild-type and various mutant enzymes with altered DNA affinity. European journal of biochemistry 1986. link